🔗 Share this article

While the United States undertakes unprecedented changes to its vaccination guidelines, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by questioning coronavirus vaccinations throughout the global health crisis and has concentrated on alleged fatalities after Covid immunization in her short position at the FDA.

Proposed Changes to Pediatric Immunization Schedule

Agency leaders planned to announce major changes to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish vaccine program, according to reports – a significant shift that would place the US at odds with a large portion of the world with insufficient data for improved outcomes. The planned update has been postponed until the next year.

Rather than the director of the vaccine center, Dr. Høeg is listed to present at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this calendar year.

A Shift at the Agency

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling long-standing vaccines at the FDA.

Høeg has repeatedly called for ending specific childhood immunization guidelines in the US in order to be more in line with Denmark, a society with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has continued to focus on immunizations – typically the domain of Dr. Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Questions Over Expertise

Høeg has no apparent experience in drug development, regulation or leadership, which has been typical for former heads of the CBER. She has served at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a large organization. She is not an expert in pharmaceutical oversight.”

Former directors of the center would “understand regulatory frameworks and the science of medication creation”, noted Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who ran the center have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock pointed out.

“The public just zeroes in on the new drug program, but the generic drug division authorizes a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and all of those need to be supervised,” she said. “The area you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a major leadership element to the role, which manages in excess of 5,000 employees. “It’s a massive administrative position, if you do it right,” she concluded.

Official Statement and Contentious Policies

When asked about questions about Høeg’s credentials and whether this assignment represents more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “concerns rely on flawed assumptions”.

“Her experience aligns with the responsibilities of her role,” the representative explained, noting the time Dr. Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the commissioner’s controversial priority voucher program, a controversial expedited drug-approval program that apparently worried her predecessors. “How are these medications being selected for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There’s a lot of secrecy occurring at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards more relaxed regulations of all drugs, with the exception of immunizations.”

Public History on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if problematic, track record, some experts have noted. She published a study using non-validated volunteer-provided data to determine the incidence of myocarditis following Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to imply Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new federal leadership featured altering regulations for new vaccines and ending “unnecessary” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has allegedly suggested excluding teenage boys from obtaining Covid vaccines.

“She’s an complete ideologue who begins with her conclusions and works backwards to retrofit the science in a very misleading, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|